X-linked Adrenoleukodystrophy in Twenty One Czech Patients
Dvořáková L.1, Hřebíček M.1, Jahnová H.1, Starý J.3, Seidl Z.4, Leiská A.4, Zeman J.1,2
Ústav dědičných metabolických poruch 1. LF UK a VFN, Praha1 přednosta prof. MUDr. M. Elleder, DrSc. Klinika dětského a dorostového lékařství 1. LF UK a VFN, Praha2 přednosta doc. MUDr. J. Hoza, CSc. Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha3 přednosta prof. MUDr. J. Starý, DrSc. Radiodiagnostická klinika 1. LF UK a VFN, Praha4 přednosta doc. MUDr. J. Daneš, CSc. |
|
Summary:
X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative metabolic disorder inherited
in an X-linked recessive manner. During the last 15 years the authors diagnosed 21 patients with
different X-ALD phenotypes. The patients were followed for 1–12 years. Progressive cerebral form
of the disease (cALD) was identified in eight boys and in two adolescent patients. Chronic adrenomyeloneuropathy
(AMN) and adrenal insufficiency only (ADO) were diagnosed in six adolescent/
adult men and in two male patients (aged 6 and 26 years), respectively. Genotyping of relatives
in affected families revealed three asymptomatic males with X-ALD (2, 6 and 29 years old,
respectively). Each of 21 patients had elevated concentrations of very long chain fatty acids
(VLCFA) in plasma and each carried a pathogenic mutation in the ABCD1 gene. The prognosis is
not favorable in the majority of patients. However, early diagnosis, carrier identification and
genetic prevention represent an important help for the affected families. Bone marrow transplantation
is effective only in early diagnosed cALD patients.
Dietary therapy includes low fat diet with Lorenzo’s oil, which inhibits endogenous VLCFA
synthesis. It is used in males with a risk of development of cerebral ALD. The effect of dietotherapy
in men with AMN is not fully proven.
Key words:
ABCD1 gene, Addison disease, adrenomyeloneuropathy, very long chain fatty acids
(VLCFA), X-linked adrenoleukodystrophy, peroxisome
|